May 23, 2025
IMUNON Announces Withdrawal of Form S-1 Registration Statement
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with…
Pharmaceuticals, Biotechnology and Life Sciences
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with…
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…
ImCheck Reports High Remission Rates in AML Patientswith ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and…
An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and…
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical…
· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile…
Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system…
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events…
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris,…
Public offering results in gross proceeds of $57.5 millionPrivate placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md.,…